Medicine and Dentistry
Metastatic Colorectal Cancer
100%
Colorectal Carcinoma
63%
Overall Survival
57%
Neoplasm
40%
Malignant Neoplasm
39%
Metastatic Carcinoma
35%
Progression Free Survival
27%
Diseases
24%
Radiation Therapy
23%
Surgery
22%
Clinical Trial
20%
Hazard Ratio
20%
Biological Marker
20%
Breast Cancer
19%
Non Small Cell Lung Cancer
19%
Epidermal Growth Factor Receptor
18%
Chemoradiotherapy
18%
Cancer Registry
17%
Cancer Therapy
17%
Fluorouracil
16%
Cancer
16%
Medical Oncology
15%
Arm
15%
Meta-Analysis
14%
Systemic Therapy
13%
Cetuximab
13%
Primary Tumor
13%
Fluoropyrimidine
13%
Circulating Tumor DNA
13%
Panitumumab
13%
Immune Checkpoint Inhibitor
13%
Cancer Survival
12%
Recurrent Disease
12%
Esophageal Adenocarcinoma
12%
Immunotherapy
12%
Rectum Cancer
12%
Adjuvant Therapy
12%
Cisplatin
11%
Randomized Controlled Trial
11%
Clinician
11%
Oncologist
11%
Pooled Analysis
11%
Diagnosis
10%
Cancer Mortality
10%
Abdominal Cancer
10%
Adverse Event
10%
Hepatectomy
10%
Group Trial
10%
Oncology
9%
Proportional Hazards Model
9%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
85%
Chemotherapy
61%
Colorectal Carcinoma
53%
Overall Survival
46%
Cetuximab
38%
Neoplasm
38%
Progression Free Survival
31%
Malignant Neoplasm
29%
Epidermal Growth Factor Receptor
28%
Biological Marker
27%
Clinical Trial
23%
Irinotecan
19%
Diseases
19%
Fluorouracil
18%
Non Small Cell Lung Cancer
16%
Chemoradiation Therapy
15%
Immune Checkpoint Inhibitor
14%
Circulating Tumor DNA
13%
Group Trial
12%
Monoclonal Antibody
11%
Adverse Event
11%
Panitumumab
11%
Randomized Controlled Trial
11%
Atezolizumab
11%
Cancer Registry
10%
Oxaliplatin
10%
Fluoropyrimidine
10%
Cisplatin
9%
Recurrent Disease
9%
Esophageal Adenocarcinoma
9%
Proton Pump Inhibitor
8%
Rectum Cancer
8%
Metastasis
8%
Biological Product
7%
Cohort Study
7%
Monotherapy
6%
Cancer of Unknown Primary Site
6%
Durvalumab
6%
Placebo
6%
Immunotherapy
6%
Pharmacokinetic
6%
Bevacizumab
6%
Pancreas Cancer
5%
Combination Therapy
5%
Docetaxel
5%
Obesity
5%
Cancer Mortality
5%
Abdominal Cancer
5%